<DOC>
	<DOCNO>NCT01672411</DOCNO>
	<brief_summary>In Europe , prostate cancer ( PCa ) common solid neoplasm , incidence rate 214 case per 1000 men , outnumber lung colorectal cancer . Early detection test develop order identify PCa still confine prostate gland . The two commonly used test digital rectal examination serum prostate-specific antigen ( PSA ) level : however , case detect call T1c stage , i.e . PSA increase . As marker , PSA organ-specific cancer-specific , level may change result physical activity , sexual activity , presence benign prostatic hyperplasia ( BPH ) , acute chronic prostatitis , well presence PCa . A total serum PSA 4.0 ng/ml traditionally use threshold consider prostate biopsy large program early detection prostate cancer show almost 70 % cancer case detect use PSA cutoff 4.0 ng/ml . However , use PSA threshold 4.0 ng/ml 20 % 25 % prostate cancer case detect ( false-negative ) false-positive rate 65 % . To improve usefulness PSA identifying patient require biopsy , PSA threshold lower 2 ng/ml ; moreover , level free bound PSA assess , together PSA density ( rate PSA prostate volume ) PSA velocity ( rate PSA increase ) , seem validity detect prostate cancer . Recent study show new biomarkers could use diagnosis early prostate cancer show high sensitivity specificity . In last two year , several investigator show PSA isoform [ −2 ] proPSA ( p2PSA ) derivative , namely , percentage p2PSA free PSA ( % p2PSA ) Prostate Health Index [ PHI ; ( p2PSA / free PSA ) × √tPSA ) ] improve accuracy total PSA ( tPSA ) percentage free PSA ( % fPSA ) predict presence PCa prostate biopsy also relate PCa aggressiveness biopsy . The aim study confirm diagnostic prognostic predictive value prostate-specific antigen isoform p2psa derivates , % p2psa prostate health index detection prostate cancer patient PSA 2-10 ng/ml and/or suspicious DRE .</brief_summary>
	<brief_title>Predictive Value Prostate-specific Antigen Isoform p2psa Its Derivates Diagnosis Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men age 1875 Total serum PSA 2.010 ng/ml entry and/or suspicious digital rectal examination Patients suitable prostate biopsy History PCa Previous prostate biopsy prostatic surgery History acute urinary retention within 3 month prior Use investigational market 5ARI , anabolic steroid drug antiandrogenic property within 12 month prior screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>prostate cancer , PSA , marker , diagnosis , prognosis , pro-PSA</keyword>
</DOC>